---
company: eHealth, Inc.
ticker: EHTH
form: 8-K
filed: 2026-05-06
accession: 0001333493-26-000025
source: https://www.sec.gov/Archives/edgar/data/1333493/000133349326000025/
---

# eHealth (EHTH) earnings release, May 6, 2026

eHealth, Inc. (EHTH) · Form 8-K, Item 2.02 · Filed 2026-05-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1333493/000133349326000025/)

eHealth, Inc. Announces First Quarter 2026 Results

Q1 2026 results ahead of expectations

Strong Medicare segment profitability and operating expense improvements YoY

Launches lifetime advisory model and final expense insurance offering

On track to reduce total FY 2026 operating costs by approximately $90M

INDIANAPOLIS — May 6, 2026 — eHealth, Inc. (Nasdaq: EHTH), a leading private online health insurance marketplace, today announced its financial results for the first quarter ended March 31, 2026.

■

Q1 2026 total revenue of $88.0 million decreased 22% compared to Q1 2025 total revenue of $113.1 million, reflecting lower Medicare approved members, consistent with our strategy to reduce variable and fixed expenses in fiscal 2026 and focus demand generation on our more profitable marketing channels.

■

Q1 2026 positive net adjustment revenue of $8.0 million compared to $10.5 million in Q1 2025.

■

Q1 2026 constrained lifetime value (“LTV”) of commissions improved across all Medicare products year-over-year, reflecting:

■ a 3% increase in Medicare Advantage (“MA”) plans;

■ a 19% increase in Medicare Supplement plans; and

■ a 78% increase in Medicare Part D plans.

■

Q1 2026 total operating costs and expenses decreased 16% to $90.9 million compared to $108.3 million in Q1 2025.

■

Variable marketing spend within our Medicare segment declined 45% year-over-year.

■

Q1 2026 non-GAAP total operating costs and expenses

(1) decreased 21% year-over-year.

■

Significant expansion in Q1 2026 Medicare segment gross margin to 41% from 34% in Q1 2025.

■

Q1 2026 Medicare unit economics improved year-over-year, driven by higher MA constrained LTV of commissions and a 10% reduction in total acquisition cost per MA-equivalent approved member.

■

Medicare LTV-to-CAC ratio

(8) of 1.4x, up from 1.2x in Q1 2025.

■

Q1 2026 GAAP net loss of $4.7 million compared to Q1 2025 GAAP net income of $2.0 million primarily due to Q1 2026 restructuring charges of $6.4 million.

■

Q1 2026 GAAP net loss margin of 5% compared to Q1 2025 GAAP net income margin of 2%.

■

Q1 2026 adjusted EBITDA

(1) of $9.0 million declined 28% compared to Q1 2025 adjusted EBITDA

(1) of $12.5 million.

■

Q1 2026 adjusted EBITDA margin

(1) of 10% compared to Q1 2025 adjusted EBITDA margin

(1) of 11%.

■

Operating cash flow of $35.8 million for the three months ended March 31, 2026; on-track to achieve operating cash flow guidance for FY 2026.

■

Cash, cash equivalents and short-term marketable securities of $110.8 million as of March 31, 2026.

■

Commissions receivable balance of $1.0 billion as of March 31, 2026.

__________

Note: See the tables at the end of this press release for a reconciliation of our GAAP financial measures to our non-GAAP financial measures for the relevant periods and footnote (1) on page¹⁴ at the end of this press release for definitions of our non-GAAP financial measures. Additionally, see accompanying footnotes on page¹⁴ for additional definitions.¹

2026 Guidance

Based on information available as of May 6, 2026, we are reiterating guidance for the full year ending December 31, 2026. These expectations are forward-looking statements and we assume no obligation to update these statements. Actual results may be materially different and are affected by the risk factors and uncertainties identified in this press release and in eHealth’s annual and quarterly reports filed with the Securities and Exchange Commission.

The following guidance is for the full year ending December 31, 2026:

• Total revenue is expected to be in the range of $405.0 million to $445.0 million.

• GAAP net income is expected to be in the range of $8.0 million to $25.0 million.

• Adjusted EBITDA

(1) is expected to be in the range of $55.0 million to $75.0 million.

• Operating cash flow is expected to be in the range of $(10.0) million to $12.0 million.

The above guidance includes the expected impact of positive net adjustment revenue which has been updated to be in the range of $8 million to $20 million to reflect the Q1 2026 positive net adjustment revenue, compared to the previous range of $0 to $20 million.

__________

Note: See accompanying footnotes on page¹⁴.

Webcast and Conference Call Information

A webcast and conference call will be held today, Wednesday, May 6, 2026 at 5:00 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing (833) 461-5787. The participant passcode is 615629308. The live and archived webcast of the call will also be available under “Events & Presentations” on the Investor Relations page of our website at https://ir.ehealthinsurance.com.

About eHealth, Inc.

For nearly 30 years, eHealth, Inc. has helped millions of Americans find the healthcare coverage that fits their needs at a price they can afford, using data, artificial intelligence and a consumer-first approach to help people quickly and effectively compare insurance options. As a leading independent licensed insurance agency and advisor, eHealth offers access to plans from more than 180 health insurers, including national and regional companies, supporting consumers during their working years and retirement. eHealth’s team of licensed insurance agents help match consumers with the insurance plans, services, and support they need to live healthier, more financially secure lives. For more, visit eHealth.com or follow us on

LinkedIn,

Facebook,

Instagram, and

X.

Forward-Looking Statements... (truncated)ned lifetime values of commissions per approved member by product category; our estimates regarding commissions receivable collection; our estimates regarding costs per approved member; our expectations regarding our profitability and our strategic plans and initiatives, including our lifetime advisory model, product diversification efforts, cost management and cash flow generation, and our ability to execute our operational and strategic plans and initiatives; our 2026 annual guidance for total revenue, GAAP net income, adjusted EBITDA and operating cash flow, and our ability to achieve our financial targets; our estimates for positive net adjustment revenue and its expected impact on our 2026 annual guidance; our expectations regarding our industry and market trends, including market opportunity, consumer demand and our competitive advantage; and other statements regarding our future operations, financial condition, prospects and business strategies.

These forward-looking statements are inherently subject to various risks and uncertainties that could cause actual results to differ materially from the statements made. In particular, we are required by Accounting Standards Codification 606 — Revenue from Contracts with Customers to make numerous assumptions that are based on historical trends and our management’s judgment.²

These assumptions may change over time and have a material impact on our revenue recognition, guidance, and results of operations. Please review the assumptions stated in this press release carefully.

The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to retain existing members and enroll new members during the annual healthcare open enrollment period, the Medicare annual enrollment period, the Medicare Advantage open enrollment period and other special enrollment periods; changes in laws, regulations and guidelines, including in connection with healthcare reform or with respect to the marketing and sale of Medicare plans; competition, including competition from government-run health insurance exchanges and marketplaces, and other sources; the seasonality of our business and the fluctuation of our operating results; our ability to accurately estimate membership, lifetime value of commissions and commissions receivable; changes in product offerings among carriers on our ecommerce platform and changes in our estimated conversion rate of an approved member to a paying member and the resulting impact of each on our commission revenue; the concentration of our revenue with a small number of health insurance carriers; our ability to execute on our growth strategy and other business initiatives; changes in our senior management or other key employees; our ability to recruit, train, retain and ensure the productivity of licensed insurance agents, or benefit advisors, and other personnel; exposure to security risks and our ability to safeguard the security and privacy of confidential data; our relationships with health insurance carriers; the success of our carrier advertising and sponsorship program; our success in marketing and selling health insurance plans and our unit cost of acquisition; our ability to effectively manage our operations as our business evolves and execute on our business plan and other strategic initiatives; the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products; changes in the market for private health insurance; consumer satisfaction of our service and actions we take to improve the quality of enrollments; changes in member conversion rates; changes in commission rates; our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy-eligible individuals through government-run health insurance exchanges and marketplaces; our ability to derive desired benefits from investments in our business, including membership growth and retention initiatives; our reliance on marketing partners; the success and cost of our marketing efforts, including branding, online advertising, direct-to-consumer mail, email, social media, telephone, SMS text, television, radio and other marketing efforts; our ability to contact our consumers or market our products through specific channels; timing of receipt and accuracy of commission reports; payment practices of health insurance carriers; risks associated with our operations in China; the restrictions in our debt obligations; the restrictions in our investment agreement with our convertible preferred stock investor; our ability to raise additional capital, including debt or equity financings, on terms acceptable to us or at all; compliance with insurance, privacy, cybersecurity and other laws and regulations; the outcome of litigation, government enforcement actions or regulatory inquiries in which we are or may from time to time be involved, including the complaint filed against us and certain defendants by the U.S. Attorney’s Office for the District of Massachusetts on May 1, 2025 alleging the violation of the Federal False Claims Act; the performance, reliability and availability of our information technology systems and our ability to maintain and improve such systems, ecommerce platform and underlying network infrastructure, including any new systems we may implement; our ability to deploy new and evolving technologies, such as artificial intelligence; public health crises, pandemics, natural disasters and other extreme events; general economic and macroeconomic conditions, including the risks of potential delays, reductions or disruptions in payments from a prolonged government shutdown, inflation, recession, political events, instability or geopolitical tensions, tariffs and trade tensions or other international disputes, financial, banking and credit market disruptions; our ability to effectively administer our self-insurance program; and other risks and uncertainties related to our business. Other factors that could cause our operating, financial and other results to differ are described in our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on the Investor Relations page of our website at https://ir.ehealthinsurance.com and on the Securities and Exchange Commission’s website at www.sec.gov.

We have based these forward-looking statements on our current expectations about future events, and these statements are not guarantees of future performance. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Relations Contact

Kate Sidorovich, CFA

Senior Vice President, Investor Relations & Corporate Development investors@ehealth.com https://ir.ehealthinsurance.com³

## Financial statements

### Income Statement (Three Months Ended March 31, — (in thousands, except per share amounts, unaudited))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2026 | 2025 | 2025 | % Change |
|---|---:|---:|---:|---:|---:|
| Revenue: | Commission |  | 79,807 |  | 98,946 | -19.0% |
| Revenue: | Other | 8,211 |  | 14,173 |  | -42.0% |
| Revenue: | Total revenue | 88,018 |  | 113,119 |  | -22.0% |
| Operating costs and expenses(a): | Marketing and advertising | 25,393 |  | 41,189 |  | -38.0% |
| Operating costs and expenses(a): | Customer care and enrollment | 32,284 |  | 37,221 |  | -13.0% |
| Operating costs and expenses(a): | Technology and content | 11,335 |  | 12,601 |  | -10.0% |
| Operating costs and expenses(a): | General and administrative | 15,512 |  | 17,310 |  | -10.0% |
| Operating costs and expenses(a): | Impairment, restructuring and other charges | 6,372 |  |  |  |  |
| Operating costs and expenses(a): | Total operating costs and expenses | 90,896 |  | 108,321 |  | -16.0% |
| Operating costs and expenses(a): | Income (loss) from operations | -2,878 |  | 4,798 |  | -160.0% |
| Operating costs and expenses(a): | Interest expense | -4,035 |  | -2,648 |  | -52.0% |
| Operating costs and expenses(a): | Other income, net | 840 |  | 1,576 |  | -47.0% |
| Operating costs and expenses(a): | Income (loss) before income taxes | -6,073 |  | 3,726 |  | -263.0% |
| Operating costs and expenses(a): | Provision for (benefit from) income taxes | -1,359 |  | 1,776 |  |  |
| Operating costs and expenses(a): | Net income (loss) | -4,714 |  | 1,950 |  | -342.0% |
| Operating costs and expenses(a): | Preferred stock dividends | -6,133 |  | -5,781 |  |  |
| Operating costs and expenses(a): | Change in preferred stock redemption value | -7,260 |  | -6,141 |  |  |
| Operating costs and expenses(a): | Net loss attributable to common stockholders |  | -18,107 |  | -9,972 | -82.0% |
| Net loss per share attributable to common stockholders: | Basic and diluted | -0.58 |  | -0.33 |  | -76.0% |
| Weighted-average number of shares used in per share: | Basic and diluted | 31,132 |  | 29,997 |  | 4.0% |
| _____________________________ (a) Includes stock-based compensation expense as follows: | Marketing and advertising | 268 |  | 497 |  |  |
| _____________________________ (a) Includes stock-based compensation expense as follows: | Customer care and enrollment | 224 |  | 264 |  |  |
| _____________________________ (a) Includes stock-based compensation expense as follows: | Technology and content | 328 |  | 688 |  |  |
| _____________________________ (a) Includes stock-based compensation expense as follows: | General and administrative | 1,438 |  | 2,340 |  |  |
| _____________________________ (a) Includes stock-based compensation expense as follows: | Total stock-based compensation expense |  | 2,258 |  | 3,789 | -40.0% |
| Non-GAAP Results(1): | Adjusted EBITDA(1) |  | 9,010 |  | 12,521 | -28.0% |
| Non-GAAP Results(1): | Adjusted EBITDA margin(1) | 10 | % | 11 | % |  |

### Income Statement (Three Months Ended March 31, — The results of our reportable segments are summarized for the periods presented below:)

| | Three Months Ended March 31, – 2026 | 2025 | % Change |
|---|---:|---:|---:|
| Medicare: | Total revenue | 81,271 | 103,669 | -22.0% |
| Medicare: | Variable marketing and advertising | -18,729 | -33,753 | 45.0% |
| Medicare: | Medicare CC&E | -29,612 | -34,469 | 14.0% |
| Medicare: | Cost of revenue | 106 | 300 | -65.0% |
| Medicare: | Medicare segment gross profit | 33,036 | 35,747 | -8.0% |

### Income Statement (Three Months Ended March 31, — The results of our reportable segments are summarized for the periods presented below:)

| | Three Months Ended March 31, – 2026 | 2025 | % Change |
|---|---:|---:|---:|
| Employer and Individual: | Total revenue | 6,747 | 9,450 | -29.0% |
| Employer and Individual: | Variable marketing and advertising | -843 | -1,190 | 29.0% |
| Employer and Individual: | E&I CC&E | -2,142 | -2,180 | 2.0% |
| Employer and Individual: | Cost of revenue | -66 | -92 | 28.0% |
| Employer and Individual: | E&I segment gross profit | 3,696 | 5,988 | -38.0% |

### Income Statement (Three Months Ended March 31, — (in thousands, unaudited))

| | Three Months Ended March 31, – 2026 | 2025 | % Change |
|---|---:|---:|---:|
| Consolidated: | Total revenue | 88,018 | 113,119 | -22.0% |
| Consolidated: | Variable marketing and advertising | -19,572 | -34,943 | 44.0% |
| Consolidated: | Segment CC&E | -31,754 | -36,649 | 13.0% |
| Consolidated: | Cost of revenue | 40 | 208 | -81.0% |
| Consolidated: | Total segment gross profit | 36,732 | 41,735 | -12.0% |

### Income Statement (Three Months Ended March 31, — A reconciliation of our segment gross profit to the Condensed Consolidated Statements of Operations for the periods presented is as follows:)

| | Three Months Ended March 31, – 2026 | 2025 | % Change |
|---|---:|---:|---:|
| Total segment gross profit | 36,732 | 41,735 | -12.0% |
| Other marketing and advertising(a) | -5,861 | -6,454 | 9.0% |
| Other CC&E(b) | -530 | -572 | 7.0% |
| Technology and content | -11,335 | -12,601 | 10.0% |
| General and administrative | -15,512 | -17,310 | 10.0% |
| Impairment, restructuring and other charges | -6,372 |  |  |
| Interest expense | -4,035 | -2,648 | -52.0% |
| Other income, net | 840 | 1,576 | -47.0% |
| Income (loss) before income taxes | -6,073 | 3,726 | -263.0% |

### Income Statement (Three Months Ended March 31, — :)

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2026 | 2025 | 2025 |
|---|---:|---:|---:|---:|
| GAAP net loss attributable to common stockholders |  | -18,107 |  | -9,972 |
| Preferred stock dividends | 6,133 |  | 5,781 |  |
| Change in preferred stock redemption value | 7,260 |  | 6,141 |  |
| GAAP net income (loss) | -4,714 |  | 1,950 |  |
| Stock-based compensation expense | 2,258 |  | 3,789 |  |
| Depreciation and amortization | 3,258 |  | 3,934 |  |
| Impairment, restructuring and other charges | 6,372 |  |  |  |
| Interest expense | 4,035 |  | 2,648 |  |
| Other income, net | -840 |  | -1,576 |  |
| Provision for (benefit from) income taxes | -1,359 |  | 1,776 |  |
| Adjusted EBITDA(1) |  | 9,010 |  | 12,521 |
| Net income (loss) margin | -5 | % | 2 | % |
| Adjusted EBITDA margin(1) | 10 | % | 11 | % |

### Balance Sheet (March 31, 2026 — (in thousands, unaudited))

| | March 31, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 75,112 | 73,725 |
| Current assets: | Short-term marketable securities | 35,702 | 3,495 |
| Current assets: | Accounts receivable | 1,537 | 7,688 |
| Current assets: | Contract assets – commissions receivable – current | 212,143 | 236,116 |
| Current assets: | Prepaid expenses and other current assets | 12,115 | 13,328 |
| Current assets: | Total current assets | 336,609 | 334,352 |
| Current assets: | Contract assets – commissions receivable – non-current | 824,435 | 886,614 |
| Current assets: | Property and equipment, net | 4,596 | 4,531 |
| Current assets: | Operating lease right-of-use assets | 7,642 | 8,429 |
| Current assets: | Restricted cash | 3,090 | 3,090 |
| Current assets: | Other assets | 24,735 | 25,452 |
| Current assets: | Total assets | 1,201,107 | 1,262,468 |
| Current liabilities: | Accounts payable | 5,592 | 28,323 |
| Current liabilities: | Accrued compensation and benefits | 21,144 | 41,009 |
| Current liabilities: | Accrued marketing expenses | 4,729 | 16,182 |
| Current liabilities: | Lease liabilities – current | 6,924 | 7,349 |
| Current liabilities: | Other current liabilities | 5,960 | 6,207 |
| Current liabilities: | Total current liabilities | 44,349 | 99,070 |
| Current liabilities: | Long-term debt | 113,761 | 112,954 |
| Current liabilities: | Deferred income taxes – non-current | 55,699 | 57,223 |
| Current liabilities: | Lease liabilities – non-current | 12,511 | 14,050 |
| Current liabilities: | Other non-current liabilities | 5,139 | 5,519 |
| Current liabilities: | Total liabilities | 231,459 | 288,816 |
| Current liabilities: | Convertible preferred stock | 393,917 | 382,057 |
| Stockholders’ equity: | Common stock | 45 | 44 |
| Stockholders’ equity: | Additional paid-in capital | 763,617 | 761,495 |
| Stockholders’ equity: | Treasury stock, at cost | -199,998 | -199,998 |
| Stockholders’ equity: | Retained earnings | 12,009 | 30,116 |
| Stockholders’ equity: | Accumulated other comprehensive income (loss) | 58 | -62 |
| Stockholders’ equity: | Total stockholders’ equity | 575,731 | 591,595 |
| Stockholders’ equity: | Total liabilities, convertible preferred stock and stockholders’ equity | 1,201,107 | 1,262,468 |

### Cash Flow (Three Months Ended March 31, — (in thousands, unaudited))

| | Three Months Ended March 31, – 2026 | 2025 |
|---|---:|---:|
| Operating activities: | Net income (loss) | -4,714 | 1,950 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Depreciation and amortization | 490 | 471 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Amortization of internally developed software | 2,768 | 3,463 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Stock-based compensation expense | 2,258 | 3,789 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Deferred income taxes | -1,524 | 1,529 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | Other non-cash items | 346 | -306 |
| Changes in operating assets and liabilities: | Accounts receivable | 6,151 | 13,421 |
| Changes in operating assets and liabilities: | Contract assets – commissions receivable | 86,437 | 77,048 |
| Changes in operating assets and liabilities: | Prepaid expenses and other assets | 159 | -978 |
| Changes in operating assets and liabilities: | Accounts payable | -23,127 | -16,034 |
| Changes in operating assets and liabilities: | Accrued compensation and benefits | -19,865 | 1,087 |
| Changes in operating assets and liabilities: | Accrued marketing expenses | -11,453 | -7,541 |
| Changes in operating assets and liabilities: | Deferred revenue | -2,815 | -332 |
| Changes in operating assets and liabilities: | Accrued expenses and other liabilities | 654 | -446 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 35,765 | 77,121 |
| Investing activities: | Capitalized internal-use software and website development costs | -2,150 | -3,118 |
| Investing activities: | Purchases of property and equipment and other assets | -155 | -308 |
| Investing activities: | Purchases of marketable securities | -35,554 | -27,362 |
| Investing activities: | Proceeds from redemption and maturities of marketable securities | 3,500 | 36,260 |
| Investing activities: | Net cash provided by (used in) investing activities | -34,359 | 5,472 |
| Financing activities: | Repurchase of shares to satisfy employee tax withholding obligations | -160 | -699 |
| Financing activities: | Net cash used in financing activities | -160 | -699 |
| Financing activities: | Effect of exchange rate changes on cash, cash equivalents and restricted cash | 141 | 1 |
| Financing activities: | Net increase in cash, cash equivalents and restricted cash | 1,387 | 81,895 |
| Financing activities: | Cash, cash equivalents and restricted cash at beginning of period | 76,815 | 42,287 |
| Financing activities: | Cash, cash equivalents and restricted cash at end of period | 78,202 | 124,182 |
